Future study of CML patient CD34+ stem/progenitor cell lipid profiles may highlight whether this specific regulatory function of PPARγ is involved in the CML TKI-response. The gene discussed is PPARG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.